| ELICIO THERAPEUTICS |
| USA |
| Gesundheit |
| US28657F1030 / A3CY4J |
| 9HA (Frankfurt) / ELTX (NASDAQ) |
| FRA:9HA, ETR:9HA, 9HA:GR, NASDAQ:ELTX |
| - |
| https://elicio.com/ |
|
Elicio Therapeutics Inc. is a clinical-stage biotechnology company developing lymph node-targeted immunotherapies for the treatment of cancer. The company's proprietary Amphiphile platform delivers immunotherapeutics directly to lymph nodes, the brai..
>Volltext.. |
| 169.89 Mio. EUR |
| 166.44 Mio. EUR |
| - |
| -31.69 Mio. EUR |
| -34.28 Mio. EUR |
| -2.22 EUR |
| 12.57 Mio. EUR |
| 16.08 Mio. EUR |
| -32.01 Mio. EUR |
| 2.29 |
| - |
| 32.79% |
| - |
| - |
| - |
| - |
| ELICIO |
| 04.04.26 |
|